December 2020
-
CT Findings of COVID-19 Pneumonia and Mimicking Diseases in Patients With Lung Cancer
The COVID-19 pandemic has caused more than 43.2 million cumulative cases and 1.16 million deaths, as of late October 2020. Approximately 1% of patients with COVID-19 have malignancy,1 and lung […]
-
EGFR/ALK-Mutated NSCLC: Using Real-world Therapeutic Practices to Help Answer Real-world Therapeutic Questions
ILCN Editorial Group member Shirish M. Gadgeel, MD, is Chief of the Division of Hematology/Oncology at the Henry Ford Cancer Institute/Henry Ford Hospital. Dr. Gadgeel is currently working, in conjunction […]
-
SBRT Versus Surgery in the COVID-19 Era: What Has Changed and What Hasn't?
Surgery is considered the preferred treatment in patients with lung cancer who are fit to undergo the procedure. Stereotactic radiotherapy (SBRT) is guideline recommended for patients who are unfit for […]
-
Increasing Understanding about the Role Biosimilar Agents in Everyday Practice: A Q&A with Dr. Gary Lyman (Part 1 of 2)
In September 2017, the FDA approved bevacizumab-awwb for the treatment of NSCLC, with the same indications as the tradename agent. Although bevacizumab-awwb is the only biosimilar agent specific to lung […]
-
Osimertinib Approved as Adjuvant Therapy for NSCLC with Certain EGFR Mutations
December 18, 2020—The U.S. Food and Drug Administration (FDA) approved osimertinib as post-resection adjuvant therapy for patients with NSCLC and EGFR exon 19 deletions or exon 21 L858R mutations, as […]
-
Leora Horn, MD, MSc, FRCPC
Leora Horn, MD, MSc, FRCPC, has joined AstraZeneca as the Global Head of Lung Cancer Strategy. Prior to joining AstraZeneca in September 2020, Dr. Horn was an Associate Professor of […]
-
Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
Associate Professor of Nursing at Yale University, Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, added Fellow of the American Academy of Nursing (FAAN) to her impressive list […]
-
Interstitial Lung Abnormality, Interstitial Lung Disease, and Lung Cancer
As a practicing chest radiologist in Boston, one of this article’s authors (Dr. Hatabu) encounters several patients with drug-related pneumonitis (DRP) daily when on clinical duty. Sometimes DRP coexists with […]
-
Alexander Drilon, MD
Alexander Drilon, MD, is now Memorial Sloan Kettering Cancer Center’s Chief of the Early Drug Development (EDD) Service in the Division of Solid Tumor Oncology of the Department of Medicine. […]
-
Pembrolizumab Is Active in Lung Cancer Brain Metastases
In Reference To: Goldberg SB, Schalper KA, Gettinger SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, […]
View ILCN Archives
Provider Resources